|
Douglas I. Hepler Ph.D. joined the Company's Board of Directors in March of 2004. Dr. Hepler is currently Vice President of Research and Development for IDEXX Pharmaceuticals Inc. a wholly owned subsidiary of IDEXX Laboratories Inc. Dr. Hepler is responsible for the overall technical leadership of the Pharmaceutical Division of IDEXX Pharmaceuticals Inc. Dr. Hepler was also the Co-founder and Executive Vice President of Blue Ridge Pharmaceuticals Inc. before its sale to IDEXX Laboratories Inc. in 1998. While at Blue Ridge Pharmaceuticals Dr. Hepler was instrumental in the development and FDA registration of Acarexx Iverhart Plus PZI Vet Facilitator Navigator Pyrantel and CyFly. Prior to Blue Ridge Pharmaceuticals Dr. Hepler was instrumental in the development and FDA registration of Interceptor Program and Sentenial while at Novartis Animal Health. Dr. Hepler received a B.S. degree from Lock Haven University in biology a M.S. from Colorado State University in microbiology and a Ph.D. from Colorado State University in immunology. | 